MeSH D016471 - ovarian hyperstimulation syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals | Ganirelix | Ganirelix | 2022-04-07 | |||
| EMD Serono | Cetrorelix | Cetrotide | 2000-08-11 | |||
| Gedeon Richter | Ganirelix | Ganirelix Gedeon Richter | 2022-07-15 | |||
| Gland Pharma | Ganirelix | Ganirelix | 2023-02-28 | |||
| Cetrorelix | Cetrorelix | 2024-04-25 | ||||
| Lupin Research | Ganirelix | Ganirelix | 2023-11-16 | |||
| Meitheal Pharmaceuticals | Ganirelix | Ganirelix | 2022-06-06 | |||
| Merck & Co | Cetrorelix | Cetrotide | 1999-04-12 | |||
| Organon | Ganirelix | Ganirelix | 1999-07-29 | $59 M | Q1/23-Q1/24 | |
| Ganirelix | Orgalutran | 2000-05-16 | $125 M | Q3/22-Q2/23 | ||
| Qilu Pharmaceuticals | Cetrorelix | Cetrorelix | 2024-04-16 | |||
| Sun Pharmaceutical Industries | Ganirelix | Fyremadel | 2018-11-30 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
86%6/7
Phase 2
36%4/11
Phase 3
73%8/11
Approved: 2Overall Success rate: 23%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use